Abstract
TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Protein & Peptide Letters
Title: Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Volume: 19 Issue: 3
Author(s): Rui Wang, Shiliang Zhou, Xiaomin Peng, Xin-Wen Zhou, Zhi-Qun Xie, Yuxiong Wang, Wei Mo and Min Yu
Affiliation:
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Abstract: TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Export Options
About this article
Cite this article as:
Wang Rui, Zhou Shiliang, Peng Xiaomin, Zhou Xin-Wen, Xie Zhi-Qun, Wang Yuxiong, Mo Wei and Yu Min, Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris, Protein & Peptide Letters 2012; 19 (3) . https://dx.doi.org/10.2174/092986612799363136
DOI https://dx.doi.org/10.2174/092986612799363136 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Important Classes of Bioactive Alkaloids from Marine Ascidians: Structures, Isolation and Bioactivity
Current Topics in Medicinal Chemistry Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry The Involvement of Post-Translational Modifications in Alzheimer's Disease
Current Alzheimer Research IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Two Novel Lectins from Parkia biglandulosa and Parkia roxburghii: Isolation, Physicochemical Characterization, Mitogenicity and Anti- Proliferative Activity
Protein & Peptide Letters Current Strategies to Overcome Resistance to ALK-Inhibitor Agents
Current Drug Metabolism Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry Treatment of Diffuse-Type Gastric Cancer Cells Using 213Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination
Current Radiopharmaceuticals ADP-Ribosylated Proteins as Old and New Drug Targets for Anticancer Therapy: The Example of ARF6
Current Pharmaceutical Design An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes
Mini-Reviews in Medicinal Chemistry The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Gene Expression Profiling in Rodent Models for Schizophrenia
Current Neuropharmacology State of the Art in African Trypanosome Drug Discovery
Current Topics in Medicinal Chemistry SPECT-CT and PET-CT in Oncology - An Overview
Current Medical Imaging Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery STAT3: A Potential Drug Target for Tumor and Inflammation
Current Topics in Medicinal Chemistry Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Current HIV Research Ocular Vascular Involvement in the Rheumatic Diseases
Current Rheumatology Reviews Anticipation in Lynch Syndrome: Where We Are Where We Go
Current Genomics